

## Glucose Monitoring Device Market to 2019

Technology Adoption and Increasing Health Awareness Serve as Distinct Regional Growth Drivers



## GBI Research Report Guidance


- The report covers both type 1 and type 2 diabetes mellitus for estimation of the global glucose monitoring devices market.
- The report begins with an executive summary capturing the major factors driving the growth of the global glucose monitoring devices market.
- Chapter three provides an overview of the glucose monitoring devices that are included in the scope of the report.
- Chapter four provides information on the market size for the historic period (2005–2012) and the forecast period (2012–2019). The chapter also provides information on key company shares in the global glucose monitoring devices market. The chapter discusses the key trends and market dynamics that are expected to impact future growth. Market estimation does not cover non-invasive glucose monitoring devices, however qualitative analysis on non-invasive devices has been included since approval of these devices could lead to rapid growth of this market in the future.
- Chapter five discusses blood glucose meters, blood glucose test strips and lancets. The market sizes for the historic and forecast period are provided for each segment.
- Chapter six gives information on the market size for the historic and forecast period for the US, Japan, Germany, UK, France, Brazil, Italy, China, Canada, Australia, Spain and India, with cross-country analysis
- Chapter seven provides information on the healthcare reimbursement system for the US, Japan, Germany, UK, France, Brazil, Italy and Spain.
- Chapter Eight comprises profiles of the leading glucose monitoring devices companies, outlining their products, features and benefits
- Chapter nine focuses on the pipeline products for each segment. The key pipeline products are listed and discussed in detail alongside product approval and expected launch dates.
- Chapter ten discusses the deals that took place in the glucose monitoring devices industry between 2008 and 2012.

## Executive Summary

The global glucose monitoring devices market is expected to grow at a Compound Annual Growth Rate (CAGR) of XX% from \$XX billion in 2012 to \$XX billion in 2019.

The Global Glucose Monitoring Devices Market is Forecast to Grow at a Compound Annual Growth Rate of XX% During 2012–2019, to Exceed \$XX Billion in 2019

The following figure shows the projected revenue growth of the global glucose monitoring market during the 2012–2019 period.



The global glucose monitoring devices market is expected to grow at a Compound Annual Growth Rate (CAGR) of XX% from \$XX billion in 2012 to \$XX billion in 2019. Major factors driving the market are the increasing incidence of diabetes across the world, gradually improving awareness about the benefits of regular glucose monitoring, and the availability of advanced solutions for monitoring based on technologies such as Continuous Glucose Monitoring (CGM), that increase the efficiency of the testing procedures. In efforts to increase physician adoption, a number of manufacturers have focused on training and education programs which are expected to drive the adoption of these devices in a big way. Emerging markets such as India and China show potential for market growth as they are home to the world's largest patient population. However, high prices and lack of knowledge of handling advanced glucose monitoring technologies could be a restraining factor for emerging markets.

## 1 Table of Contents

1	Table of Contents.....	8
1.1	List of Tables.....	11
1.2	List of Figures.....	12
2	Introduction.....	14
3	Global Glucose Monitoring Device Market: Device Overview .....	15
3.1	Glucose Monitoring Devices.....	15
3.1.1	<i>Blood Glucose Meter</i> .....	15
3.1.2	<i>Blood Glucose Testing Strips</i> .....	15
3.1.3	<i>Lancets</i> .....	15
4	Global Glucose Monitoring Device Market: Market Characterization.....	16
4.1	Global Glucose Monitoring Device Market, Revenue (\$bn), 2005–2012.....	16
4.2	Glucose Monitoring Device Market, Revenue (\$bn), 2012–2019 .....	17
4.3	Glucose Monitoring Device Market, Global, Key Company Shares (%), 2012.....	18
4.4	Glucose Monitoring Device Market, Key Trends.....	20
4.4.1	<i>Integrated CGM – Insulin pump Systems</i> .....	20
4.4.2	<i>New Market Entrants to Change the Market Dynamics</i> .....	21
4.4.3	<i>Awareness Campaigns and Education Programs Result in Better Prevention and Treatment Plans</i> .....	22
4.5	Market Dynamics.....	23
4.5.1	<i>Market Drivers</i> .....	23
4.5.2	<i>Market Restraints</i> .....	27
5	Global Glucose Monitoring Device Market: Segment Analysis and Forecasts.....	29
5.1	Blood Glucose Test Strips Market, Global, Revenue, 2005–2012 .....	29
5.2	Blood Glucose Test Strips Market, Global, Revenue (\$bn), 2012–2019.....	30
5.3	Blood Glucose Meters Market, Global, Revenue (\$m), 2005–2012 .....	31
5.4	Blood Glucose Meters Market, Global, Revenue, 2012–2019 .....	32
5.5	Lancets Market, Global, Revenue, 2005–2012 .....	33
5.6	Lancets Market, Global, Revenue (\$m), 2012–2019 .....	34
6	Global Glucose Monitoring Device Market: Country Analysis and Forecasts.....	35
6.1	Glucose Monitoring Device Market: Cross-country Analysis .....	35
6.2	Historic and Forecast Revenue, by Country.....	37
6.2.1	<i>Glucose Monitoring Device Market, US, Revenue (\$m), 2005–2012</i> .....	37
6.2.2	<i>Glucose Monitoring Device Market, US, Revenue (\$m), 2012–2019</i> .....	38
6.2.3	<i>Glucose Monitoring Device Market, Japan, Revenue (\$m), 2005–2012</i> .....	39
6.2.4	<i>Glucose Monitoring Device Market, Japan, Revenue (\$m), 2012–2019</i> .....	40
6.2.5	<i>Glucose Monitoring Device Market, Germany, Revenue (\$m), 2005–2012</i> .....	41
6.2.6	<i>Glucose Monitoring Device Market, Germany, Revenue (\$m), 2012–2019</i> .....	42
6.2.7	<i>Glucose Monitoring Device Market, India, Revenue (\$m), 2005–2012</i> .....	43
6.2.8	<i>Glucose Monitoring Device Market, India, Revenue (\$m), 2012–2019</i> .....	44
6.2.9	<i>Glucose Monitoring Device Market, France, Revenue (\$m), 2005–2012</i> .....	45
6.2.10	<i>Glucose Monitoring Device Market, France, Revenue (\$m), 2012–2019</i> .....	46
6.2.11	<i>Glucose Monitoring Device Market, UK, Revenue (\$m), 2005–2012</i> .....	47
6.2.12	<i>Glucose Monitoring Device Market, UK, Revenue (\$m), 2012–2019</i> .....	48
6.2.13	<i>Glucose Monitoring Device Market, Canada, Revenue (\$m), 2005–2012</i> .....	49
6.2.14	<i>Glucose Monitoring Device Market, Canada, Revenue (\$m), 2012–2019</i> .....	50
6.2.15	<i>Glucose Monitoring Device Market, Spain, Revenue (\$m), 2005–2012</i> .....	51
6.2.16	<i>Glucose Monitoring Device Market, Spain, Revenue (\$m), 2012–2019</i> .....	52
6.2.17	<i>Glucose Monitoring Device Market, Italy, Revenue (\$m), 2005–2012</i> .....	53
6.2.18	<i>Glucose Monitoring Device Market, Italy, Revenue (\$m), 2012–2019</i> .....	54
6.2.19	<i>Glucose Monitoring Device Market, China, Revenue (\$m), 2005–2012</i> .....	55

6.2.20	<i>Glucose Monitoring Device Market, China, Revenue (\$m), 2012–2019</i> .....	56
6.2.21	<i>Glucose Monitoring Device Market, Australia, Revenue (\$m), 2005–2012</i> .....	57
6.2.22	<i>Glucose Monitoring Device Market, Australia, Revenue (\$m), 2012–2019</i> .....	58
6.2.23	<i>Glucose Monitoring Device Market, Brazil, Revenue (\$m), 2005–2012</i> .....	59
6.2.24	<i>Glucose Monitoring Device Market, Brazil, Revenue (\$m), 2012–2019</i> .....	60
<b>7</b>	<b>Global Glucose Monitoring Device Market: Reimbursement System</b> .....	<b>61</b>
7.1	US .....	62
7.2	Europe .....	63
7.2.1	<i>Germany</i> .....	63
7.2.2	<i>France</i> .....	63
7.2.3	<i>Italy</i> .....	63
7.2.4	<i>Spain</i> .....	63
7.2.5	<i>UK</i> .....	64
7.3	Asia-Pacific .....	64
<b>8</b>	<b>Global Glucose Monitoring Device Market: Competitive Landscape</b> .....	<b>65</b>
8.1	Comparison of Key Continuous Glucose Monitoring Systems .....	66
8.2	F. Hoffmann-La Roche Ltd. .....	67
8.2.1	<i>Business Overview</i> .....	67
8.2.2	<i>Marketed Products</i> .....	67
8.2.3	<i>SWOT Analysis</i> .....	68
8.3	LifeScan .....	68
8.3.1	<i>Business Overview</i> .....	68
8.3.2	<i>Marketed Products</i> .....	69
8.3.3	<i>SWOT Analysis</i> .....	69
8.4	Bayer Healthcare AG .....	70
8.4.1	<i>Business Overview</i> .....	70
8.4.2	<i>Marketed Products</i> .....	70
8.4.3	<i>SWOT Analysis</i> .....	71
8.5	Abbott Laboratories .....	71
8.5.1	<i>Business Overview</i> .....	71
8.5.2	<i>Marketed Products</i> .....	71
8.5.3	<i>SWOT Analysis</i> .....	72
8.6	Arkay, Inc. .....	72
8.6.1	<i>Business Overview</i> .....	72
8.6.2	<i>Marketed Products</i> .....	72
8.6.3	<i>SWOT Analysis</i> .....	73
<b>9</b>	<b>Global Glucose Monitoring Device Market: Product Pipeline Analysis</b> .....	<b>74</b>
9.1	Glucose Monitoring Devices Market: List of Pipeline Products .....	75
9.2	Glucose Monitoring Devices Market: Profiles of Key Pipeline Products .....	81
9.2.1	<i>5th Generation Short-Term Sensor</i> .....	81
9.2.2	<i>Integrated Guardian Real-Time Continuous Glucose Monitoring System</i> .....	81
9.2.3	<i>OptiScannner</i> .....	82
9.2.4	<i>EyeSense Blood Glucose Measurement Device</i> .....	82
9.2.5	<i>MD Watch</i> .....	82
9.2.6	<i>GlySens Continuous Glucose Sensor</i> .....	83
9.2.7	<i>IvSCGM Biosensor</i> .....	83
9.2.8	<i>Dario</i> .....	84
<b>10</b>	<b>Global Glucose Monitoring Device Market: Consolidation Landscape</b> .....	<b>85</b>
10.1	Deals Summary (2004–2013) .....	85
10.2	Key Deals (2008–2012) .....	85
10.2.1	<i>Roche Diagnostics Distribution Agreement with DexCom</i> .....	85
10.2.2	<i>Bayer HealthCare Diabetes Care's Partnership with Medtronic</i> .....	85

10.2.3	<i>Insulet's Acquisition of Neighborhood Diabetes</i> .....	86
10.2.4	<i>EyeSense's Agreement with Qiagen</i> .....	86
10.2.5	<i>Bionime and Ypsomed's Agreement to Market Blood Glucose Monitoring Products</i> .....	86
10.2.6	<i>ARKRAY's Distribution Agreement with Nipro</i> .....	86
10.2.7	<i>Edwards Lifesciences' Agreement with DexCom</i> .....	87
<b>11</b>	<b>Appendix.....</b>	<b>88</b>
11.1	Definitions.....	88
11.1.1	<i>Blood Glucose Meter</i> .....	88
11.1.2	<i>Blood Glucose Testing Strips</i> .....	88
11.1.3	<i>Lancets</i> .....	88
11.2	Acronyms.....	88
11.3	Sources.....	89
11.4	Research Methodology.....	91
11.4.1	<i>Secondary Research</i> .....	91
11.4.2	<i>Primary Research</i> .....	91
11.4.3	<i>Models</i> .....	92
11.4.4	<i>Forecasts</i> .....	92
11.4.5	<i>Expert Panels</i> .....	92
11.5	Contact Us.....	92
11.6	Disclaimer.....	93

SAMPLE

### 1.1 List of Tables

Table 1: Glucose Monitoring Device Market, Global, Revenue (\$bn), 2005–2012.....	16
Table 2: Glucose Monitoring Device Market, Global, Revenue (\$bn), 2012–2019 .....	17
Table 3: Glucose Monitoring Device Market, Global, Key Company Share (%), 2012.....	19
Table 4: Glucose Monitoring Devices Market, Global, Key Product Launches, 2011–2012 .....	25
Table 5: Blood Glucose Test Strips Market, Global, Revenue (\$bn), 2005–2012.....	29
Table 6: Blood Glucose Test Strips Market, Global, Revenue Forecast (\$bn), 2012–2019.....	30
Table 7: Blood Glucose Meters Market, Global, Revenue (\$m), 2005–2012 .....	31
Table 8: Blood Glucose Meters Market, Global, Revenue (\$m), 2012–2019 .....	32
Table 9: Lancets Market, Global, Revenue (\$m), 2005–2012.....	33
Table 10: Lancets Market, Global, Revenue Forecast (\$m), 2012–2019.....	34
Table 11: Glucose Monitoring Devices Market, Global, Cross Country Analysis, CAGR (%), 2005–2019 .....	35
Table 12: Glucose Monitoring Device Market, US, Revenue (\$m), 2005–2012.....	37
Table 13: Glucose Monitoring Device Market, US, Revenue (\$m), 2012–2019.....	38
Table 14: Glucose Monitoring Device Market, Japan, Revenue (\$m), 2005–2012 .....	39
Table 15: Glucose Monitoring Device Market, Japan, Revenue (\$m), 2012–2019 .....	40
Table 16: Glucose Monitoring Device Market, Germany, Revenue (\$m), 2005–2012.....	41
Table 17: Glucose Monitoring Device Market, Germany, Revenue (\$m), 2012–2019.....	42
Table 18: Glucose Monitoring Device Market, India, Revenue (\$m), 2005–2012 .....	43
Table 19: Glucose Monitoring Device Market, India, Revenue (\$m), 2012–2019 .....	44
Table 20: Glucose Monitoring Device Market, France, Revenue (\$m), 2005–2012.....	45
Table 21: Glucose Monitoring Device Market, France, Revenue (\$m), 2012–2019.....	46
Table 22: Glucose Monitoring Device Market, UK, Revenue (\$m), 2005–2012 .....	47
Table 23: Glucose Monitoring Device Market, UK, Revenue (\$m), 2012–2019 .....	48
Table 24: Glucose Monitoring Device Market, Canada, Revenue (\$m), 2005–2012 .....	49
Table 25: Glucose Monitoring Device Market, Canada, Revenue (\$m), 2012–2019 .....	50
Table 26: Glucose Monitoring Device Market, Spain, Revenue (\$m), 2005–2012 .....	51
Table 27: Glucose Monitoring Device Market, Spain, Revenue (\$m), 2012–2019 .....	52
Table 28: Glucose Monitoring Device Market, Italy, Revenue (\$m), 2005–2012 .....	53
Table 29: Glucose Monitoring Device Market, Italy, Revenue (\$m), 2012–2019 .....	54
Table 30: Glucose Monitoring Device Market, China, Revenue (\$m), 2005–2012 .....	55
Table 31: Glucose Monitoring Device Market, China, Revenue (\$m), 2012–2019 .....	56
Table 32: Glucose Monitoring Device Market, Australia, Revenue (\$m), 2005–2012 .....	57
Table 33: Glucose Monitoring Device Market, Australia, Revenue (\$m), 2012–2019 .....	58
Table 34: Glucose Monitoring Device Market, Brazil, Revenue (\$m), 2005–2012 .....	59
Table 35: Glucose Monitoring Device Market, Brazil, Revenue (\$m), 2012–2019 .....	60
Table 36: Roche, Key Marketed Products, 2013 .....	67
Table 37: LifeScan, Key Marketed Products, 2013 .....	69
Table 38: Bayer Healthcare AG, Key Marketed Products, 2013 .....	70
Table 39: Abbott Laboratories, Key Marketed Products, 2013 .....	71
Table 40: Arkray Inc., Key Marketed Products, 2013 .....	72
Table 41: Glucose Monitoring Devices Market, Global, List of Pipeline Products, 2013a.....	75
Table 42: Glucose Monitoring Devices Market, Global, List of Pipeline Products, 2013b.....	76
Table 43: Glucose Monitoring Devices Market, Global, List of Pipeline Products, 2013c.....	77
Table 44: Glucose Monitoring Devices Market, Global, List of Pipeline Products, 2013d.....	78
Table 45: Glucose Monitoring Devices Market, Global, List of Pipeline Products, 2013e.....	79
Table 46: Glucose Monitoring Devices Market, Global, List of Pipeline Products, 2013f.....	80
Table 47: Glucose Monitoring Devices Market, Global, List of Pipeline Products, 2013g.....	80
Table 48: 5th Generation Short-term Sensor, Product Status, 2013.....	81
Table 49: Integrated Guardian Real-Time Continuous Glucose Monitoring System, Product Status, 2013.81	81
Table 50: OptiScannner, Product Status, 2013 .....	82
Table 51: EyeSense Blood Glucose Measurement Device, Product Status, 2013.....	82
Table 52: MD Watch, Product Status, 2013.....	82
Table 53: GlySens Continuous Glucose Sensor, Product Status, 2013.....	83
Table 54: IvSCGM Biosensor, Product Status, 2013 .....	83
Table 55: Dario, Product Status, 2013.....	84

## 1.2 List of Figures

Figure 1: Glucose Monitoring Device Market, Timeline for Glucose Monitoring .....	14
Figure 2: Glucose Monitoring Device Market, Device Overview .....	15
Figure 3: Glucose Monitoring Device Market, Global, Revenue (\$bn), 2005–2012 .....	16
Figure 4: Glucose Monitoring Device Market, Global, Revenue (\$bn), 2012–2019 .....	17
Figure 5: Glucose Monitoring Device Market, Global, Key Company Share by Revenue (%), 2012 .....	18
Figure 6: Glucose Monitoring Device Market, Market Trends .....	20
Figure 7: Glucose Monitoring Market, Global, Leading Integrated CGM-Insulin Pump Systems, 2013 .....	21
Figure 8: Glucose Monitoring Market, EU5, National Policies for Prevention and Treatment of Diabetes, 2013 .....	22
Figure 9: Glucose Monitoring Device Market, Market Dynamics .....	23
Figure 10: Glucose Monitoring Market, Product Launches, US, 2012–2013 .....	25
Figure 11: Glucose Monitoring Market, US, Clinical Trials Elucidating Effects Of CGM In The Treatment Of Type 1 Diabetes Mellitus, 2010 .....	26
Figure 12: Blood Glucose Test Strips Market, Global, Revenue (\$bn), 2005–2012 .....	29
Figure 13: Blood Glucose Test Strips Market, Global, Revenue Forecast (\$bn), 2012–2019 .....	30
Figure 14: Blood Glucose Meters Market, Global, Revenue (\$m), 2005–2012 .....	31
Figure 15: Blood Glucose Meters Market, Global, Revenue Forecast (\$m), 2012–2019 .....	32
Figure 16: Lancets Market, Global, Revenue (\$m), 2005–2012 .....	33
Figure 17: Lancets Market, Global, Revenue Forecast (\$m), 2012–2019 .....	34
Figure 18: Glucose Monitoring Device Market, Global, Cross-Country Analysis, CAGR (%), 2005–2019 .....	35
Figure 19: Glucose Monitoring Device Market, Top 12 Countries, Number of Diabetes Cases ('000s), 2011, Mean Diabetes Related Expenditure Per Person with Diabetes (\$), 2013 .....	36
Figure 20: Glucose Monitoring Device Market, US, Revenue (\$m), 2005–2012 .....	37
Figure 21: Glucose Monitoring Device Market, US, Revenue (\$m), 2012–2019 .....	38
Figure 22: Glucose Monitoring Device Market, Japan, Revenue (\$m), 2005–2012 .....	39
Figure 23: Glucose Monitoring Device Market, Japan, Revenue (\$m), 2012–2019 .....	40
Figure 24: Glucose Monitoring Device Market, Germany, Revenue (\$m), 2005–2012 .....	41
Figure 25: Glucose Monitoring Device Market, Germany, Revenue (\$m), 2012–2019 .....	42
Figure 26: Glucose Monitoring Device Market, India, Revenue (\$m), 2005–2012 .....	43
Figure 27: Glucose Monitoring Device Market, India, Revenue (\$m), 2012–2019 .....	44
Figure 28: Glucose Monitoring Device Market, France, Revenue (\$m), 2005–2012 .....	45
Figure 29: Glucose Monitoring Device Market, France, Revenue (\$m), 2012–2019 .....	46
Figure 30: Glucose Monitoring Device Market, UK, Revenue (\$m), 2005–2012 .....	47
Figure 31: Glucose Monitoring Device Market, UK, Revenue (\$m), 2012–2019 .....	48
Figure 32: Glucose Monitoring Device Market, Canada, Revenue (\$m), 2005–2012 .....	49
Figure 33: Glucose Monitoring Device Market, Canada, Revenue (\$m), 2012–2019 .....	50
Figure 34: Glucose Monitoring Device Market, Spain, Revenue (\$m), 2005–2012 .....	51
Figure 35: Glucose Monitoring Device Market, Spain, Revenue (\$m), 2012–2019 .....	52
Figure 36: Glucose Monitoring Device Market, Italy, Revenue (\$m), 2005–2012 .....	53
Figure 37: Glucose Monitoring Device Market, Italy, Revenue (\$m), 2012–2019 .....	54
Figure 38: Glucose Monitoring Device Market, China, Revenue (\$m), 2005–2012 .....	55
Figure 39: Glucose Monitoring Device Market, China, Revenue (\$m), 2012–2019 .....	56
Figure 40: Glucose Monitoring Device Market, Australia, Revenue (\$m), 2005–2012 .....	57
Figure 41: Glucose Monitoring Device Market, Australia, Revenue (\$m), 2012–2019 .....	58
Figure 42: Glucose Monitoring Device Market, Brazil, Revenue (\$m), 2005–2012 .....	59
Figure 43: Glucose Monitoring Device Market, Brazil, Revenue (\$m), 2012–2019 .....	60
Figure 44: Glucose Monitoring Device Market, Reimbursement System in Key Geographies .....	61
Figure 45: Glucose Monitoring Market, US, Medicare Reimbursement, Coding and Billing, 2013 .....	62
Figure 46: Glucose Monitoring Device Market, Global, Competitive Assessment, 2013 .....	65
Figure 47: Glucose Monitoring Device Market, Global, Heat Map, 2013 .....	66
Figure 48: Glucose Monitoring Devices Market, F. Hoffmann-La Roche Ltd., SWOT Analysis, 2013 .....	68
Figure 49: Glucose Monitoring Devices Market, LifeScan, SWOT Analysis, 2013 .....	69
Figure 50: Glucose Monitoring Devices Market, Bayer Healthcare, SWOT Analysis, 2013 .....	71
Figure 51: Glucose Monitoring Devices Market, Abbott Laboratories, SWOT Analysis, 2013 .....	72
Figure 52: Glucose Monitoring Devices Market, Arkray, Inc., SWOT Analysis, 2013 .....	73

Figure 53: Global Glucose Monitoring Device Market, Pipeline Products Summary, 2013.....	74
Figure 54: Global Glucose Monitoring Device Market, Deals Summary, 2013.....	85

SAMPLE

## 2 Introduction

**Figure 1: Glucose Monitoring Device Market, Timeline for Glucose Monitoring**

	<p>1965: Ames Company launch Dextrostix, a strip of paper that changes color to indicate the patient's glucose levels after a drop of blood is applied.</p> <p>1971: The first patent for a blood glucose meter is awarded to Anton Hubert Clemens on September 14, 1971. This meter is known as the Ames reflectance meter and is able to quantify the strip's color for a more accurate glucose measurement.</p> <p>1978: Availability of first home literature on diabetic blood glucose</p> <p>1981: The first home glucose monitoring device Glucometer was launched by Bayer</p> <p>1986: The FDA, CDC and ADA recognize self monitoring of glucose as key to efficient management of diabetes</p> <p>1987: Supply side initiatives to introduce low cost home glucose meters improves access to diabetes care.</p> <p>1993: National Institute of Diabetes and Digestive and Kidney Diseases publishes results of a study showing that patients who practice self-monitoring of glucose reduced chances of complications by 76% for eye disease, 50% for kidney disease, and 60% for nerve disease.</p> <p>2006: The first CGM system launches, this device is implanted under the skin.</p> <p>2008: Integration of glucose monitoring and insulin delivery.</p>
	<p>CGM: Continuous Glucose Monitoring</p> <p>Source: GBI Research</p>

The blood glucose monitoring market is one of the fastest growing markets. With the huge growth in the incidence of diabetes there is a corresponding demand for effective treatment options. Regular monitoring of glucose levels has been shown to be both clinically and economically beneficial, preventing associated health conditions including cardiovascular diseases, diabetic retinopathy and neuropathy.

The US remains the largest market in terms of the revenue generated by the global glucose monitoring devices in 2012; given the rise in patient population, healthcare spending and the emergence of new technologies is expected to retain its position during the forecast period. The availability of reimbursement for traditional glucose monitoring devices is another driving factor. However, the reimbursement for Continuous Glucose Monitoring (CGM), though available, is limited to type XX diabetes patients and excludes type XX diabetics. This coupled with the high initial costs of CGM devices may limit adoption.


Emerging markets despite having the largest patient populations (in terms of absolute number of patients), suffer from low penetration of glucose monitoring devices, especially technologically advanced products. The lack of disease awareness, absence of reimbursement, and the urban-rural divide reduce the number of growth opportunities, despite a huge potential.

The glucose monitoring competitive landscape is largely dominated by established players. Most products offered by these companies cater to the traditional glucose monitoring sector that is gradually reaching maturity and commodity status. The introduction of technologically innovative and clinically beneficial CGM technology is expected to encourage new players to enter the market. Though these new entrants currently occupy only a small share of the overall market, the uptake of CGM technology may cause a significant shift in market shares.

## 4 Global Glucose Monitoring Device Market: Market Characterization

### 4.1 Global Glucose Monitoring Device Market, Revenue (\$bn), 2005–2012

The following figure shows the revenues generated by global glucose monitoring device market for the 2005–2012 period.



The following table shows the revenues generated by global glucose monitoring device market for the 2005–2012 period.

**Table 1: Glucose Monitoring Device Market, Global, Revenue (\$bn), 2005–2012**

	2005	2006	2007	2008	2009	2010	2011	2012	CAGR (%)
Blood glucose test strips									
Blood glucose meters									
Lancets									
<b>Total</b>									

Source: GBI Research's proprietary database [accessed December 4, 2013]


CAGR: Compound Annual Growth Rate

The global glucose monitoring market was valued at \$XX billion in 2005 and grew at a CAGR of XX% to reach \$XX billion in 2012. The increasing global prevalence of diabetes, and improving awareness of the benefits of regular glucose monitoring in diabetes treatment and management were major growth drivers. In 2012 there were a global total of XX million diabetics and XX million adults with impaired glucose tolerance (IDF, 2012). This shows that there is a significant need for routine monitoring of glucose levels. Blood glucose test strips were the most successful product, of the three types covered, over the period a value of \$XX billion in 2005 that increased to \$XX billion in 2012, at a CAGR of XX%.

## 9 Global Glucose Monitoring Device Market: Product Pipeline Analysis

A significant XX% of the pipeline products in this market are classified as class XX devices.

The following figure shows the percentage of pipeline products in each stage of development.



The impact of new product launches with technical advances on the future growth of this market may not take effect in the short-term future. A significant XX% of the pipeline products in this market are classified as class XX devices. These are primarily devices that have integrated glucose monitoring and insulin delivery functions which involve greater risk than standalone devices which are either used for glucose monitoring or insulin delivery. Class XX devices are subject to greater scrutiny during the approval process which results in significant additional costs and delays over class XX devices. Class XX devices may take several years to complete clinical studies to prove their equivalence or superiority over currently available marketed products. In comparison, class II devices receive regulatory approval at a much faster pace which ranges from three to XX months. Therefore, companies involved in the development of integrated glucose monitoring and insulin delivery devices can expect much longer approval processes before their products can be made available in respective geographies.

The global glucose monitoring devices market comprises XX products in the pipeline with the majority products located in the clinical stage of development (XX products, approximately XX% of the total pipeline). The forecast period is expected to witness numerous product launches since majority of the pipeline products are in the clinical stage of development. A high demand for advanced glucose monitoring products is driving the development of technologically innovative products based on emerging technology platforms such as non-invasive blood glucose monitoring technologies such as, EyeSense and NMB-200G, insulin pumps integrated with CGM; Integrated Guardian Real-Time Continuous Glucose Monitoring System and devices with connectivity to smartphones and other devices through mobile apps. Innovative technology and improved functional features will drive the demand and for the glucose monitoring devices, with both niche companies and established market players capitalizing on this trend.

Majority of pipeline products are classified as class XX devices which go through relatively less rigor in terms of time and cost involved in receiving regulatory approvals. However.

## 11 Appendix

### 11.1 Definitions

#### 11.1.1 Blood Glucose Meter

A blood glucose meter is used to determine the approximate concentration of blood glucose levels. Currently, two types of blood glucose monitors are used: traditional glucose meters and CGM systems. Minimally invasive and non-invasive blood glucose meters are not covered in this report.

#### 11.1.2 Blood Glucose Testing Strips

Blood glucose testing strips are a single-use component of the diabetes monitoring system and work in conjunction with a blood glucose monitor. A drop of sample blood is placed on the strip; the blood glucose is oxidized and generates an electric signal which can be read by the glucose meter. Usually a person suffering from diabetes needs to test for blood glucose levels three to four times a day.

#### 11.1.3 Lancets

Lancets are mechanical devices which are used to prick the skin to obtain capillary blood for blood glucose monitoring. The lancet is usually held in a lancing device, which releases the lancet when triggered.

### 11.2 Acronyms

ALD:	Affections De Longue Durée
CAGR:	Compound Annual Growth Rate
CGM:	Continuous Glucose Monitoring
CPT:	Current Procedural Terminology
EU:	European Union
FDA:	US Food and Drug Administration
HbA1c:	glycated Hemoglobin
ICU:	Intensive Care Unit
IDF:	International Diabetes Federation
MDI:	Multiple Daily Injections
mg/dl:	milligrams per deciliter
mmol:	millimole
NDEP:	National Diabetes Education Program
NDP:	National Diabetes Program
NDSS:	National Diabetes Services Scheme
QALY:	Quality-Adjusted Life-Years
RDC:	Roche Diabetes Care
SMBG:	Self-Monitoring of Blood Glucose
STS:	Short-Term Sensor
USB:	Universal Serial Bus

### 11.3 Sources

- Abbott (2013). System Components. *Abbott*. Available from: <http://www.abbottdiabetescare.co.uk/your-products/freestyle-navigator/system-components> [Accessed on December 05, 2013].
- AACE (2010). Continuous Glucose Monitoring. *American Association of Clinical Endocrinologists*. Available from: <https://www.aace.com/files/continuousglucosemonitoring.pdf>
- ADA (2011). Diabetes Statistics. *American Diabetes Association*. Available from: <http://www.diabetes.org/diabetes-basics/diabetes-statistics/> [Accessed on: 20 November 2013]
- ADA (2013). The Cost of Diabetes. *American Diabetes Association*. Available from: <http://www.diabetes.org/advocate/resources/cost-of-diabetes.html> [Accessed on: 20 November 2013]
- Animas (2013). Products. Animas Vibe insulin pump and CGM System. *Animas*. Available from: <http://www.animascorp.co.uk/animas-vibe-and-cgm-system>. [Accessed on: 15 November 2013]
- Anjana, et al. (2011). ICMR-INDIAB Collaborative Study Group: Prevalence of diabetes and prediabetes (impaired fasting glucose or/and impaired glucose tolerance) in rural and urban India: Phase 1 results of the Indian Council of Medical Research-INDIA DIABetes (INDIAB) study. *Diabetologia*. 2011;54:3022-7
- APHA (2013) CMS cuts reimbursement for diabetes test supplies. *American Pharmacists Association*. Available from: <http://www.pharmacist.com/cms-cuts-reimbursement-diabetes-test-supplies>. [Accessed on: 21 November 2013]
- Arkay (2011), Reimbursement, *Arkay*. Available from: [http://www.glucocardusa.com/expression\\_reimbursement.html](http://www.glucocardusa.com/expression_reimbursement.html) [Accessed on December 05, 2013]
- Bergenstal, et al. (2010). Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1
- Diabetes. *New England Journal of Medicine*, 363(4), 311-320
- Congressional Diabetes Caucus (2013). Facts and Figures. Diabetes in the United States. *Congressional Diabetes Caucus*, Available from: <http://www.house.gov/degette/diabetes/facts.shtml>. [Accessed on: 5 December 2013]
- Eyesense (2013) About us. *Eyesense*, Available from: <http://www.eyesense.com/en/ueber.htm>. [Accessed on: 20 November 2013]
- FDA (2012), Dexcom G4 PLATINUM Continuous Glucose Monitoring System, *Food and Drug Administration*, Available from: [http://www.accessdata.fda.gov/cdrh\\_docs/pdf12/p120005a.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf12/p120005a.pdf)
- Fonda, et al. (2013) Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes (T2DM). Presented at the American Diabetes Association 72nd Scientific Sessions, June 8-12, 2012. Available from: <http://www.dexcom.com/sites/dexcom.com/files/cgm-library-downloads/cost-effectiveness-real-time-cgm.pdf>
- Garrido, et al. (2011). Adjacent-level Cervical Ossification after Bryan Cervical Disc Arthroplasty Compared with Anterior Cervical Discectomy and Fusion. *Journal of Bone and Joint Surgery-American*, Jul 6;93(13):1185-9
- IDF (2013a), IDF Diabetes Atlas, 6<sup>th</sup> Edition, *International Diabetes Federation*, Available from: [http://www.idf.org/sites/default/files/EN\\_6E\\_Atlas\\_Full\\_0.pdf](http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf)
- IDF (2013b), IDF Diabetes Atlas, 6<sup>th</sup> Edition, *International Diabetes Federation*, Available from: [http://www.idf.org/sites/default/files/EN\\_6E\\_Atlas\\_Full\\_0.pdf](http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf)
- IDF (2013c), IDF Diabetes Atlas, 6<sup>th</sup> Edition, *International Diabetes Federation*, Available from: [http://www.idf.org/sites/default/files/EN\\_6E\\_Atlas\\_Full\\_0.pdf](http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf)
- IDF (2013d), IDF Diabetes Atlas, 6<sup>th</sup> Edition, *International Diabetes Federation*, Available from: [http://www.idf.org/sites/default/files/EN\\_6E\\_Atlas\\_Full\\_0.pdf](http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf)
- Kaufman, et al. (2001) A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. *Diabetes Care*. 24(12):2030-2034.

#### 11.4.3 Models

Where no hard data is available GBI Research uses modeling and estimates in order to produce comprehensive data sets. The following rigorous methodology is adopted:

Available hard data is cross referenced with the following data types to produce estimates:

- Demographic data: population, split by segment.
- Macro-economic indicators: Gross Domestic Product, Inflation rate. .
- Healthcare Indicators: health expenditure, physician's base, healthcare infrastructure and facilities.
- Selected epidemiological and procedure statistics.

Data is then cross-checked by the expert panel.

All data and assumptions relating to modeling are stored and are available to clients on request.

#### 11.4.4 Forecasts

GBI Research uses proprietary forecast models. The following four factors are utilized in the forecast models:

- Historic growth rates.
- Macro indicators such as population trends and healthcare spending.
- Forecast epidemiological data.
- Qualitative trend information and assumptions.

Data is then cross-checked by the expert panel.

All data and assumptions relating to modeling are stored and are available to clients on request.

#### 11.4.5 Expert Panels

GBI Research uses a panel of experts to cross verify its databases and forecasts.

GBI Research's expert panel comprises marketing managers, product specialists, international sales managers from medical device companies; academics from research universities, KOLs from hospitals, consultants from venture capital funds and distributors/suppliers of medical equipment and supplies.

Historic data and forecasts are relayed to GBI Research's expert panel for feedback and adjusted in accordance with this feedback.

### ***11.6 Disclaimer***

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GBI Research.

SAMPLE